Literature DB >> 9823344

Refractive changes associated with scleral buckling and division in retinopathy of prematurity.

D R Chow1, P J Ferrone, M T Trese.   

Abstract

OBJECTIVE: To examine the refractive changes that occur in infant eyes with retinopathy of prematurity (ROP) retinal detachments that are subjected to scleral buckling and subsequent division of the scleral buckle.
METHODS: A retrospective medical record review of infants with ROP who were managed with an encircling scleral buckle that was subsequently divided and who underwent refraction evaluation during and after division of the scleral buckle.
RESULTS: Seven eyes from 6 patients had scleral exo-plants placed for stage 4 ROP retinal detachments at a mean postconceptional age of 48 weeks. The mean refractive error in eyes with the scleral buckle was -11 diopters (D) (range, -5 to -25 D) with an induced mean anisometropia of -9.5 D. After division of the scleral buckle at a mean of 36 weeks postoperatively, the average post-scleral buckle refractive error was -5.68 D, resulting in a mean myopic reduction of 5.5 D.
CONCLUSIONS: Scleral buckling in infants with ROP results in large myopic shifts, which are significantly reduced after division of the scleral buckle. This highlights the importance of repeated refraction testing in infants after placement and division of the scleral buckle to avoid refractive amblyopia.

Entities:  

Mesh:

Year:  1998        PMID: 9823344     DOI: 10.1001/archopht.116.11.1446

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Fabrication and evaluation of chitosan-gelatin based buckling implant for retinal detachment surgery.

Authors:  Hui Chen; Zhi Zhao; Yahong Zhao; Yumin Yang
Journal:  J Mater Sci Mater Med       Date:  2010-08-14       Impact factor: 3.896

Review 2.  Combined anterior and posterior segment injuries in children: a review.

Authors:  Petra Meier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-29       Impact factor: 3.117

3.  The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes.

Authors:  Yoshikazu Hatsukawa; Nami Ueki; Tomoko Yamagishi; Hiroyuki Kitajima
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

4.  Safety and efficacy of simultaneous bilateral 25-gauge lens-sparing vitrectomy for vascularly active stage 4 retinopathy of prematurity.

Authors:  P K Shah; V Narendran; N Kalpana
Journal:  Eye (Lond)       Date:  2015-05-22       Impact factor: 3.775

5.  Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.

Authors:  Emine Alyamaç Sukgen; Yusuf Koçluk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-06       Impact factor: 3.117

6.  Iris-fixated phakic intraocular lens implantation in an adult with retinopathy of prematurity: 1-year follow-up.

Authors:  Young Shin Kim; Jin Kwon Chung; Sung Jin Lee
Journal:  Int Ophthalmol       Date:  2017-05-18       Impact factor: 2.031

Review 7.  Paediatric retinal detachment: a review.

Authors:  Raffaele Nuzzi; Carlo Lavia; Roberta Spinetta
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

8.  Lens-sparing vitrectomy for stage 4 and stage 5 retinopathy of prematurity.

Authors:  Young Suk Yu; Seong-Joon Kim; So Young Kim; Ho Kyung Choung; Gyu Hyung Park; Jang Won Heo
Journal:  Korean J Ophthalmol       Date:  2006-06

9.  Surgical treatments for fibrous tissue extending to the posterior retina in eyes with familial exudative vitreoretinopathy.

Authors:  Mari Takahashi; Tadashi Yokoi; Satoshi Katagiri; Tomoyo Yoshida-Uemura; Sachiko Nishina; Noriyuki Azuma
Journal:  Jpn J Ophthalmol       Date:  2017-11-03       Impact factor: 2.447

10.  Functional and anatomical outcomes after primary lens-sparing pars plana vitrectomy for Stage 4 retinopathy of prematurity.

Authors:  Pramod Bhende; Lingam Gopal; Tarun Sharma; Aditya Verma; Rupak Kanti Biswas
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.